Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy

Kidney International, Supplement

Volumn 66, Issue 92, 2004, Pages

  Jacobsen, Peter ^a   Parving, Hans Henrik ^a  

^a NONE

Author keywords

ACE I; ACE ID polymorphism; Albuminuria; Angiotensin II receptor blockade; Blood pressure; Diabetic kidney disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VALSARTAN;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GENE DELETION; GENE INSERTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; CARDIOVASCULAR DISEASE; REVIEW; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; HUMANS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 16644378834     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09226.x     Document Type: Article

References (21)

1. PARVING H-H, ØSTERBY R, RITZ E: Diabetic nephropathy, chap. 39, in The Kidney, 6th ed., edited by Brenner BM, Philadelphia, WB Saunders, 2000, pp 1731-1773
2. LEWIS EJ, HUNSICKER LG, BAIN RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
3. CHOBANIAN AV, BAKRIS GL, BLACK HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289:2560-2572, 2003
4. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003
5. MOLITCH ME, DEFRONZO RA, FRANZ MJ, et al: Diabetic nephropathy. Diabetes Care 26(Suppl 1):S94-S98, 2003
6. PARVING H-H, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
7. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
8. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
9. MCMURRAY JJV, ÖSTERGREN J, SWEDBERG K, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362:767-771, 2003
10. NAKAO N, YOSHIMURA A, MORITA H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124, 2003
11. PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003
12. JACOBSEN P, ANDERSEN S, ROSSING K, et al: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17:1019-1024, 2002
13. JACOBSEN P, ANDERSEN S, JENSEN BR, et al: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14:992-999, 2003
14. JACOBSEN P, ANDERSEN S, ROSSING K, et al: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63:1874-1880, 2003
15. JACOBSEN P, ROSSING K, ROSSING P, et al: Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 53:1002-1006, 1998
16. JACOBSEN P, TARNOW L, CARSTENSEN B, et al: Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 14:2843-2850, 2003
17. ANDERSEN S, TARNOW L, CAMBIEN F, et al: Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype? Kidney Int 62:192-198, 2002
18. ANDERSEN S, TARNOW L, CAMBIEN F, et al: Long-term renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype? Diabetes Care 26:1501-1506, 2003
19. BAKRIS GL, WEIR MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160:685-693, 2000
20. APPERLOO AJ, DE ZEEUW D, DE JONG PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793-797, 1997
21. RUGGENENTI P, MISE N, PISONI R, et al: Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107:586-592, 2003